9.23
Precedente Chiudi:
$9.32
Aprire:
$9.45
Volume 24 ore:
1.23M
Relative Volume:
0.96
Capitalizzazione di mercato:
$492.43M
Reddito:
$1.02B
Utile/perdita netta:
$-757.20M
Rapporto P/E:
-0.6253
EPS:
-14.76
Flusso di cassa netto:
$-257.90M
1 W Prestazione:
+4.41%
1M Prestazione:
+28.91%
6M Prestazione:
+19.71%
1 anno Prestazione:
-2.84%
Emergent Biosolutions Inc Stock (EBS) Company Profile
Nome
Emergent Biosolutions Inc
Settore
Telefono
240-631-3200
Indirizzo
300 PROFESSIONAL DR, GAITHERSBURG, MD
Confronta EBS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
EBS
Emergent Biosolutions Inc
|
9.23 | 483.89M | 1.02B | -757.20M | -257.90M | -14.76 |
![]()
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
![]()
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
![]()
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-30 | Iniziato | H.C. Wainwright | Buy |
2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
2024-03-07 | Aggiornamento | The Benchmark Company | Hold → Buy |
2023-11-20 | Ripresa | JP Morgan | Underweight |
2023-08-29 | Downgrade | The Benchmark Company | Buy → Hold |
2023-04-10 | Aggiornamento | The Benchmark Company | Hold → Buy |
2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
2022-11-10 | Downgrade | The Benchmark Company | Buy → Hold |
2022-04-29 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2022-01-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
2021-11-08 | Downgrade | The Benchmark Company | Buy → Hold |
2021-05-05 | Downgrade | Argus | Buy → Hold |
2021-04-07 | Iniziato | The Benchmark Company | Buy |
2021-02-24 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
2021-02-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2020-09-14 | Ripresa | JP Morgan | Neutral |
2020-07-31 | Reiterato | Chardan Capital Markets | Buy |
2019-09-12 | Iniziato | Guggenheim | Buy |
2019-09-04 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
2018-11-02 | Aggiornamento | Goldman | Neutral → Buy |
2018-08-03 | Reiterato | Chardan Capital Markets | Buy |
2018-06-13 | Iniziato | Argus | Buy |
2018-04-25 | Downgrade | Wells Fargo | Outperform → Market Perform |
2018-01-24 | Iniziato | Goldman | Neutral |
2018-01-16 | Reiterato | Chardan Capital Markets | Buy |
2016-06-28 | Reiterato | Singular Research | Buy |
2016-04-15 | Iniziato | Chardan Capital Markets | Buy |
2016-03-28 | Iniziato | Singular Research | Buy |
2016-02-19 | Iniziato | Wells Fargo | Outperform |
2014-05-15 | Iniziato | Summer Street Research | Buy |
2011-05-31 | Reiterato | WBB Securities | Strong Buy |
2011-01-10 | Reiterato | Wedbush | Outperform |
2010-11-05 | Reiterato | Wedbush | Outperform |
2010-08-18 | Aggiornamento | WBB Securities | Buy → Strong Buy |
2010-08-06 | Reiterato | Caris & Company | Buy |
Mostra tutto
Emergent Biosolutions Inc Borsa (EBS) Ultime notizie
Analysts Apply Wyckoff Model to Emergent BioSolutions Inc. Stock2025 Market WrapUp & Fast Moving Market Watchlists - beatles.ru
Technical Bounce Expected in Emergent BioSolutions Inc. Next WeekJuly 2025 Analyst Calls & Risk Managed Trade Strategies - thegnnews.com
Emergent BioSolutions : From Cost Center to Value Driver - MarketScreener
Three Analyst Favorites with Potential for Further Gains: SkyWater Technology, Emergent BioSolutions, and More - AInvest
Is Emergent BioSolutions Inc. stock forming a cup and handleTrade Volume Summary & High Conviction Buy Zone Picks - thegnnews.com
Emergent BioSolutions Board Member Sells $67K in Company Stock Amid Revenue Decline. - AInvest
Emergent BioSolutions signs contract modification award for CNJ-016 - MSN
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact Its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEO’s Insider Sales - ACCESS Newswire
Emergent BioSolutions' (NYSE:EBS) Solid Earnings May Rest On Weak Foundations - simplywall.st
Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 27% - 富途牛牛
We Think That There Are Some Issues For Emergent BioSolutions (NYSE:EBS) Beyond Its Promising Earnings - Yahoo Finance
Emergent BioSolutions Inc. Outperforms Peers on Volume MetricsQuarterly Risk Review & Smart Allocation Stock Reports - newsyoung.net
RSI Suggests Rebound May Be Near in Emergent BioSolutions Inc.2025 Volume Leaders & Daily Stock Momentum Reports - beatles.ru
Emergent BioSolutions Director Sells 7,844 Shares at $8.65/Share on August 12, 2025. - AInvest
Emergent BioSolutions’ Earnings Call Highlights Strong Financial Performance - The Globe and Mail
Emergent BioSolutions’ Strong Q2 Fuels Hopes for 2025 Rally - citybiz
300 new jobs headed to Bayview manufacturing plant - The Business Journals
Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally - Seeking Alpha
Emergent Biosolutions: Strategic Advancements and Financial Performance Drive Buy Rating - TipRanks
Emergent BioSolutions Reports Improved Q2 2025 Results - TipRanks
Published on: 2025-08-10 18:27:00 - metal.it
Earnings Update: Here's Why Analysts Just Lifted Their Emergent BioSolutions Inc. (NYSE:EBS) Price Target To US$13.50 - simplywall.st
Emergent BioSolutions Inc. (NYSE:EBS) Q2 2025 Earnings Call Transcript - Insider Monkey
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates - MSN
Emergent BioSolutions' Strong ROE Amid Industry Average: A Financial Analysis - AInvest
Can Emergent BioSolutions Inc. (NYSE:EBS) Maintain Its Strong Returns? - Yahoo Finance
Emergent BioSolutions to participate in investor conferences in May and June 2025. - AInvest
Benchmark Co. Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Emergent BioSolutions Updates FY25 Revenue Guidance to $765M-$835M - AInvest
BioPharma Co.'s $15M Deal Over Ruined J&J Vaccines OK'd - Law360
Emergent BioSolutions Surpasses Q2 Revenue Expectations - The Globe and Mail
Emergent BioSolutions reports Q2 adjusted EPS 16c vs ($2.32) last year - TipRanks
Emergent BioSolutions Soars 22% on Earnings Surprise: What's Fueling the Surge? - AInvest
Emergent Biosolutions reports second quarter loss - Maryland Daily Record
Emergent Biosolutions shares rise 6.14% premarket after securing $51.9 million contract modification for smallpox preparedness. - AInvest
Installed Building Products reports record Q2 2025 results, 3.1% revenue increase. - AInvest
Emergent Biosolutions Q2 Earnings Report: $12 Million LossNews and Statistics - IndexBox
Emergent Biosolutions: Q2 Earnings Snapshot - Huron Daily Tribune
Emergent BioSolutions Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Emergent BioSolutions Q2 2025 results show mixed performance - Investing.com
Emergent BioSolutions Outpaces Its Own Forecasts But Misses Analyst Targets - Finimize
Emergent Biosolutions earnings beat by $0.26, revenue fell short of estimates - Investing.com Canada
Emergent BioSolutions Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Emergent BioSolutions Q2 revenue misses analyst expectations - MarketScreener
Emergent BioSolutions Inc Q2 2025 Earnings: EPS of -$0.22 Beats Estimates, Revenue Surges to $140.9 Million - GuruFocus
Emergent BioSolutions Q2 2025 slides: Profitability improves as transformation continues - Investing.com Canada
Emergent Biosolutions Q2 Earnings: Non-GAAP EPS Beats by $0.65, Revenue Misses by $5.47M - AInvest
Emergent BioSolutions Reports Second Quarter 2025 Financial Results - The Manila Times
Emergent BioSolutions Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
What drives Emergent BioSolutions Inc. stock priceInvest confidently with real-time data analysis - Jammu Links News
Is it the right time to buy Emergent BioSolutions Inc. stockMaximize your portfolio’s growth potential - Jammu Links News
Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):